WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006082597) CRYSTAL MODIFICATION OF 5-SUBSTITUTED-2-OXAZOIIDONE DERIVATIVE AND ITS PROCESS THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/082597    International Application No.:    PCT/IN2006/000024
Publication Date: 10.08.2006 International Filing Date: 24.01.2006
IPC:
C07D 263/24 (2006.01), A61P 25/00 (2006.01)
Applicants: FDC LIMITED [IN/IN]; B-8, MIDC Industrial Area, Waluj 431 136, Maharashtra (IN) (For All Designated States Except US).
CHANDAVARKAR, Mohan, Anand [IN/IN]; (IN) (For US Only).
BAPAT, Rajaram, Uday [IN/IN]; (IN) (For US Only).
KHARE, Vivek, Manohar [IN/IN]; (IN) (For US Only)
Inventors: CHANDAVARKAR, Mohan, Anand; (IN).
BAPAT, Rajaram, Uday; (IN).
KHARE, Vivek, Manohar; (IN)
Agent: NAIR, Gopakumar, G.; Patent & Trademark Agent (Regd.), Gopakumar Nair Associates, Nair Baug, Akuril Road, Kandivli (East), Mumbai 400 101 Maharashtra (IN)
Priority Data:
71/MUM/2005 24.01.2005 IN
Title (EN) CRYSTAL MODIFICATION OF 5-SUBSTITUTED-2-OXAZOIIDONE DERIVATIVE AND ITS PROCESS THEREOF
(FR) MODIFICATION CRISTALLINE DE DERIVE DE 2-OXAZOLIDONE 5-SUBSTITUEE ET PROCEDE ASSOCIE
Abstract: front page image
(EN)The present invention discloses crystalline Polymorphic Form I of compound 5-(3,5- dimethylphenoxy-) methyl)-2-oxazolidinone, characterized by x-ray diffraction pattern having peaks at 10.355, 14.285,18.625, 19.030, 20.810 and 22.475± 0.30 degrees 2 theta angle, and melting point ranging from 122.50C to 1240C which is characterized by Diffrencial Scanning Calorimetry. The present invention further discloses processes for the preparation thereof, pharmaceutical preparations comprising the said Polymorph and its use in the treatment of depression of central synaptic transmissions.
(FR)La présente invention concerne une forme I polymorphe cristalline d'un composé de 5-(3,5- diméthylphénoxy-) méthyl)-2-oxazolidinone, caractérisée par un diagramme de diffraction aux rayons X présentant des pics aux valeurs 10,355, 14,285, 18,625, 19,030, 20,810 et 22,475 ± 0,30 degrés d'angle 2 thêta, et un point de fusion compris entre 122,5 °C et 124 °C qui est caractérisé par analyse calorimétrique différentielle. La présente invention concerne également des procédés de préparation de ladite forme, des préparations pharmaceutiques comprenant ledit polymorphe et son utilisation dans le traitement de la dépression de transmissions synaptiques centrales.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)